BioPharma Dive3d
Merck bets $200M on a new type of heart pill
A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...
Hengrui Pharma signs exclusive licensing agreement for its heart disease drug with Merck & Co.
Hengrui Pharma signs exclusive licensing agreement for its heart disease drug with Merck & Co.
Medical Marketing & Media1d
Rx Rundown: Merck, Novo Nordisk, GSK and more
Merck signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals worth up to $2 billion.
Merck licenses HRS-5346 in cardiovascular disease from Hengrui Pharma
Merck (MRK) and Jiangsu Hengrui Pharmaceuticals, a global pharmaceutical company focused on scientific and technological innovation, have ...
Merck, Hengrui Pharma in Lipoprotein(a) Licensing Deal
Merck & Co. has agreed to license an investigational oral small molecule lipoprotein (a) inhibitor from Jiangsu Hengrui Pharmaceuticals in a deal potentially worth more than $2 billion to the Chinese ...
Pharmaceutical Technology on MSN3d
MSD makes licence agreement with Hengrui Pharma for Lp(a) inhibitor
MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.
PMLive3d
Merck gains rights to Hengrui’s heart disease candidate in deal worth almost $2bn
Merck & Co – known as MSD outside the US and Canada – has said it will be gaining exclusive global rights to Jiangsu Hengrui ...
Merck Will Pay Up to $2 Billion for Chinese Heart Drug Rights
Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...